{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T05:58:54Z","timestamp":1782712734801,"version":"3.54.5"},"reference-count":24,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2024,10,19]],"date-time":"2024-10-19T00:00:00Z","timestamp":1729296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Bimekizumab is a biologic targeting interleukin (IL)-17A\/17F, approved by the Food and Drug Administration (FDA) for moderate-to-severe plaque psoriasis in 2023.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Sources:<\/jats:title>\n                    <jats:p>A PubMed search was performed using the keywords \u201cbimekizumab,\u201d \u201cplaque psoriasis,\u201d and \u201cbimekizumab clinical trials,\u201d from origin to August 1, 2024. We included phase I to III trials of bimekizumab for plaque psoriasis, studies published post-FDA approval, and information from the package insert.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Selection, Data Extraction:<\/jats:title>\n                    <jats:p>We summarized 1 phase I, 4 phase II, and 4 phase III trials, and 3 real-world studies published post-FDA approval.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Synthesis:<\/jats:title>\n                    <jats:p>Bimekizumab was effective; &gt;85% and 70% of patients achieved PASI90 and PASI100, respectively, in phase III trials. Head-to-head, 85% of bimekizumab patients achieved PASI90 versus 50% of ustekinumab patients. The most frequent adverse event was oral candidiasis (4%-10%); serious adverse events were rare (&lt;1%). Long-term studies confirmed sustained efficacy and consistent safety profile.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Relevance to Patient Care and Clinical Practice in Comparison to Existing Drugs:<\/jats:title>\n                    <jats:p>Bimekizumab was more efficacious than other IL-17 inhibitors, ustekinumab, and adalimumab. Real-world data corroborate bimekizumab\u2019s efficacy. Bimekizumab had a safety profile like other IL-17 inhibitors, with higher rates of mucocutaneous candidiasis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Many patients who failed other IL-17 inhibitors and switched to bimekizumab experienced clearance. The efficacy of bimekizumab in patients who failed other IL-17 blockers may be attributable to bimekizumab\u2019s ability to block multiple IL-17 isoforms. Bimekizumab also outperformed tumor necrosis factor (TNF)-alpha inhibitors. There may be patients who fail previously available drugs, for reasons including nonadherence, antidrug antibodies, or adverse effects; bimekizumab, which targets additional cytokines, may bridge that gap.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10600280241288553","type":"journal-article","created":{"date-parts":[[2024,10,19]],"date-time":"2024-10-19T12:27:21Z","timestamp":1729340841000},"page":"577-584","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":5,"title":["Bimekizumab-bkzx for the Treatment of Plaque Psoriasis: A Drug Review"],"prefix":"10.1177","volume":"59","author":[{"given":"Margaret E.","family":"Greer","sequence":"first","affiliation":[{"name":"Center for Dermatology Research, Department of Dermatology, School of Medicine, Wake Forest University, Winston-Salem, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-2321-3254","authenticated-orcid":false,"given":"Shannon K.","family":"Moran","sequence":"additional","affiliation":[{"name":"Center for Dermatology Research, Department of Dermatology, School of Medicine, Wake Forest University, Winston-Salem, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0090-6289","authenticated-orcid":false,"given":"Steven R.","family":"Feldman","sequence":"additional","affiliation":[{"name":"Center for Dermatology Research, Department of Dermatology, School of Medicine, Wake Forest University, Winston-Salem, NC, USA"},{"name":"Department of Dermatology, School of Medicine, Wake Forest University, Winston-Salem, NC, USA"},{"name":"Department of Pathology, School of Medicine, Wake Forest University, Winston-Salem, NC, USA"},{"name":"Department of Social Sciences &amp; Health Policy, School of Medicine, Wake Forest University, Winston-Salem, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2024,10,19]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-90107-7_1"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.2174\/1574886315666200128095958"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15931"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2023.2219897"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011535.pub3"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.2147\/BTT.S252578"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18126"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/jvc2.379"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2024.103530"},{"key":"e_1_3_2_11_2","unstructured":"Bimzelx (bimekizumab) [Package insert]. Drive Smyrna GA: UCB; 2023. Accessed August 23 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761151s000lbl.pdf."},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212127"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.20827"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.03.037"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-024-02868-7"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13185"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.05.105"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2022.1185"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00125-2"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00126-4"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2102388"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljac021"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2024.05.085"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.5826\/dpc.1402a52"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljac089"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280241288553","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10600280241288553","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280241288553","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:13:52Z","timestamp":1777374832000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10600280241288553"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,19]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["10.1177\/10600280241288553"],"URL":"https:\/\/doi.org\/10.1177\/10600280241288553","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,19]]}}}